The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen

OBJECTIVE: Bortezomib is one of the important drugs that have made breakthrough progress in multiple myeloma (MM) in the past 10 years. However, the heterogeneity of its efficacy makes it difficult to predict the risk of disease progression. The purpose of this study is to determine the prognostic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Yanbin, Shao, Hong, Yang, Ziheng, Fan, Lixia, Liu, Wenwen, Shi, Jianhong, Wang, Yuqing, Han, Ying, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492571/
https://www.ncbi.nlm.nih.gov/pubmed/32984029
http://dx.doi.org/10.3389/fonc.2020.01617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492571/
https://www.ncbi.nlm.nih.gov/pubmed/32984029
http://dx.doi.org/10.3389/fonc.2020.01617

Ejemplares similares